Combined treatment of acute EAE in lewis rats with TNF-binding protein and interleukin-1 receptor antagonist

Experimental Neurology

Volumn 149, Issue 2, 1998, Pages 455-463

  Wiemann, B ^a   Van, G Y ^a   Danilenko, D M ^a   Yan, Q ^a   Matheson, C ^a   Munyakazi, L ^a   Ogenstad, S ^a   Starnes, C O ^a  

^a AMGEN INC   (United States)

Author keywords

Combination; Experimental autoimmune encephalomyelitis; Interleukin 1 receptor antagonist; Tumor necrosis factor binding protein

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BODY WEIGHT; DISEASE COURSE; DISEASE SEVERITY; FEMALE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; WEIGHT REDUCTION;

EID: 0032005559     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6723     Document Type: Article

References (56)

1. Archelos J. J., Jung S., Maurer M., Schmied M., Lassmann H., Tamatani T., Miyasaka M., Toyka K. V., Hartung H.-P. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann. Neurol. 34:1993;145-154.
2. Baker P., Kennedy M., Roux E., Picha K., Jacobs C. Effect of soluble interleukin 1 receptor (IL-1R) on experimental autoimmune encephalomyelitis (EAE). J. Leukocyte Biol. Suppl. 1:1990;63.
3. Baron J. L., Madri J. A., Ruddle N. H., Hashim G., Janeway C. A. Jr. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:1993;57-68.
4. Barten D. M., Ruddle N. H. Vascular cell adhesion molecule-1 modulation by tumor necrosis factor in experimental allergic encephalomyelitis. J. Neuroimmunol. 51:1994;123-133.
5. Bauer J., Berkenbosch F., Van Dam A.-M., Dijkstra C. D. Demonstration of interleukin-1β in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level. J. Neuroimmunol. 48:1993;13-22.
6. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations. Acta Neurol. Scand. 78:1988;318-323.
7. Cannella B., Cross A. H., Raine C. S. Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 46:1993;43-56.
8. de Vries H. E., Blom-Roosemalen M. C. M., Van Oosten M., De Boer A. G., Van Berkel T. J. C., Breimer D. D., Kuiper J. The influence of cytokines on the integrity of blood-brain barrier in vitro. J. Neuroimmunol. 64:1996;37-43.
9. Dinarello C. A., Cannon J. G., Wolff S. M., Bernheim H. A., Beutler B., Cerami A., Figari I. S., Palladino M. A. Jr., O'Connor J. V. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 163:1986;1433-1450.
10. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan F. M., Walker J., Bijl H., Ghrayeb J., Woody J. N. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum. 36:1993;1681-1690.
11. Elliott M. J., Maini R. N., Feldmann M., Kalden J. R., Antoni C., Smolen J. S., Leeb B., Breedveld F. C., Macfarlane J. D., Bijl H., Woody J. N. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
12. Elliott M. J., Maini R. N., Feldmann M., Long-Fox A., Charles P., Bijl H., Woody J. N. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 344:1994;1125-1127.
13. Fong Y., Tracey K. J., Moldawer L. L., Hesse D. G., Manogue K. B., Kenney J. S., Lee A. T., Kuo G. C., Allison A. C., Lowry S. F., Cerami A. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170:1989;1627-1633.
14. Frei K., Eugster H.-P., Bopst M., Constantinescu C. S., Lavi E., Fontana A. Tumor necrosis factor α and lymphotoxin α are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185:1997;2177-2182.
15. Gille J., Swerlick R. A., Lawley T. J., Caughman S. W. Differential regulation of vascular cell adhesion molecule-1 gene transcription by tumor necrosis factor α and interleukin-1α in dermal microvascular endothelial cells. Blood. 87:1996;211-217.
16. Hauser S. L., Doolittle T. H., Lincoln R., Brown R. H., Dinarello C. A. Cytokine accumulations in CSF of multiple sclerosis patients: Frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology. 40:1990;1735-1739.
17. Held W., Meyermann R., Qin Y., Mueller C. Perforin and tumor necrosis factor α in the pathogenesis of experimental allergic encephalomyelitis: Comparison of autoantigen induced and transferred disease in Lewis rats. J. Autoimmun. 6:1993;311-322.
18. Hershkoviz R., Mor F., Gilat D., Cohen I. R., Lider O. T cells in the spinal cord in experimental autoimmune encephalomyelitis are matrix adherent and secrete tumor necrosis factor alpha. J. Neuroimmunol. 37:1992;161-166.
19. Hofman F. M., Hinton D. R., Johnson K., Merrill J. E. Tumor necrosis factor identified in multiple sclerosis brain. J. Exp. Med. 170:1989;607-612.
20. Issazadeh S., Ljungdahl A., Hojeberg B., Mustafa M., Olsson T. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: Dynamics of mRNA expression for interleukin-10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factor β J. Neuroimmunol. 61:1995;205-212.
21. Jacobs C. A., Baker P. E., Roux E. R., Picha K. S., Toivola B., Waugh S., Kennedy M. K. Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J. Immunol. 146:1991;2983-2989.
22. Kennedy M. K., Torrance D. S., Picha K. S., Mohler K. M. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149:1992;2496-2505.
23. Kent S. J., Karlik S. J., Cannon C., Hines D. K., Yednock T. A., Fritz L. C., Horner H. C. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. 58:1995;1-10.
24. Korner H., Goodsall A. L., Lemckert F. A., Scallon B. J., Ghrayeb J., Ford A. L., Sedgwick J. D. Unimpaired autoreactive T-cell traffic within the central nervous system during tumor necrosis factor receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA. 92:1995;11066-11070.
25. Kuijpers T. W., Hakkert B. C., Hoogerwerf M., Leeuwenberg J. F. M., Roos D. Role of endothelial leukocyte adhesion molecule-1 and platelet-activating factor in neutrophil adherence to IL-1-prestimulated endothelial cells. J. Immunol. 147:1991;1369-1376.
26. Littell R. C., Milliken G. A., Stroup W. W., Wolfinger R. D. SAS System for Mixed Models. 1996;SAS Institute Inc. Cary.
27. m2. J. Exp. Med. 173:1991;1493-1500.
28. Maimone D., Gregory S., Arnason B. G. W., Reder A. T. Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J. Neuroimmunol. 32:1991;67-74.
29. Martin D., Near S. L. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J. Neuroimmunol. 61:1995;241-245.
30. Martin D., Near S. L., Bendele A., Russell D. A. Inhibition of tumor necrosis factor is protective against neurologic dysfunction after active immunization of Lewis rats with myelin basic protein. Exp. Neurol. 131:1995;221-228.
31. Matsuda M., Tsukada N., Miyagi K., Yanagisawa N. Increased interleukin-1 production by peripheral blood mononuclear cells in patients with multiple sclerosis. J. Neurol. Sci. 102:1991;100-104.
32. Merrill J. E., Strom S. R., Ellison G. W., Myers L. W. In vitro study of mediators of inflammation in multiple sclerosis. J. Clin. Immunol. 9:1989;84-96.
33. Navikas V., He B., Link J., Haglund M., Soderstrom M., Fredrikson S., Ljungdahl A., Hojeberg B., Qiao J., Olsson T., Link H. Augmented expression of tumour necrosis factor-α and lymphotoxin in mononuclear cells in multiple sclerosis and optic neuritis. Brain. 119:1996;213-223.
34. Opal S. M., Cross A. S., Jhung J. W., Young L. D., Palardy J. E., Parejo N. A., Donsky C. Potential hazards of combination immunotherapy in the treatment of experimental septic shock. J. Infect. Dis. 173:1996;1415-1421.
35. Pober J. S., Lapierre L. A., Stolpen A. H., Brock T. A., Springer T. A., Fiers W., Bevilacqua M. P., Mendrick D. L., Gimbrone M. A. Jr. Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J. Immunol. 138:1987;3319-3324.
36. Powell M. B., Mitchell D., Lederman J., Buckmeier J., Zamvil S. S., Graham M., Ruddle N. H., Steinman L. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int. Immunol. 2:1990;539-544.
37. Rentzos M., Nikolaou C., Rombos A., Voumvourakis K., Segditsa I., Papageorgiou C. Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies. J. Neurol. 243:1996;165-170.
38. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Helwig A., Poser S. Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:1995;82-88.
39. Ruddle N. H., Bergman C. M., McGrath K. M., Lingenheld E. G., Grunnet M. L., Padula S. J., Clark R. B. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172:1990;1193-1200.
40. Russell D., Tucker K., Kohno H., Thompson R. C. Inhibition of tumor necrosis factor (TNF) is effective alone or in combination with inhibition of interleukin-1 (IL-1) in reducing joint swelling in rodent bacterial cell wall-induced arthritis. Arthritis Rheum. 37:1994;S279.
41. Russell D. A., Tucker K. K., Chinookoswong N., Thompson R. C., Kohno T. Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival and organ function. J. Infect. Dis. 171:1995;1528-1538.
42. SAS/STAT Software: Changes and Enhancements Through Release 6.11. 1992;SAS Institute, Inc. Cary.
43. Selmaj K. W., Raine C. S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 23:1988;339-346.
44. Selmaj K., Raine C. S., Cross A. H. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30:1991;694-700.
45. Selmaj K. W., Raine C. S. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology. 45:1995;S44-S49.
46. Sharief M. K., Thompson E. J. In vivo relationship of tumor necrosis factor-α to blood-brain barrier damage in patients with active multiple sclerosis. J. Neuroimmunol. 38:1992;27-34.
47. Strand V. The future use of biologic therapies in combination for the treatment of rheumatoid arthritis. J. Rheumatol. 23:1996;91-96.
48. Tsukada N., Miyagi K., Matsuda M., Yanagisawa N., Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J. Neurol. Sci. 102:1991;230-234.
49. Tsukada N., Matsuda M., Miyagi K., Yanagisawa N. Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis. Neurology. 43:1993;2679-2682.
50. Villarroya H., Violleau K., Younes-Chennoufi A. B., Baumann N. Myelin-induced experimental allergic encephalomyelitis in Lewis rats: Tumor necrosis factor α levels in serum and cerebrospinal fluid - Immunohistochemical expression in glial cells and macrophages of optic nerve and spinal cord. J. Neuroimmunol. 64:1996;55-61.
51. Welsh C. T., Rose J. W., Hill K. E., Townsend J. J. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1α J. Neuroimmunol. 43:1993;161-168.
52. Willenborg D. O., Simmons R. D., Tamatani T., Miyasaka M. ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system. J. Neuroimmunol. 45:1993;147-154.
53. Williams R. O., Feldmann M., Maini R. N. Evaluation of anti-IL-1r and anti-TNF therapy in murine collagen-arthritis and comparison with combined anti-TNF/anti-CD4 therapy. Arthritis Rheum. 37:1994;S279.
54. Williams R. O., Mason L. J., Feldmann M., Maini R. N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 91:1994;2762-2766.
55. αβ. J. Exp. Med. 175:1992;993-1002.
56. Yednock T. A., Cannon C., Fritz L. C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature. 356:1992;63-66.